来源：财中社

财中社9月14日电 同源康医药-B（02410）发布公告，确认已于2024年9月13日向中国证券监督管理委员会提交了将1.7亿股非上市股份转换为H股的申请。这些股份占公司已发行股本的46.82%。此举旨在实现H股全流通，进一步推动公司的市场化进程。

公告中提到的主要股东包括郑州泰基鸿诺医药股份有限公司，持有6500万股，占比17.53%；贝沃特医药技术（上海）有限公司持有536万股，占比1.45%；成都博远嘉昱创业投资合伙企业（有限合伙）持有598万股，占比1.61%。转换后的H股将于香港联合交易所上市，具体进展将在后续公告中披露。

特别声明：以上内容仅代表作者本人的观点或立场，不代表新浪财经头条的观点或立场。如因作品内容、版权或其他问题需要与新浪财经头条联系的，请于上述内容发布后的30天内进行。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.